TABLE 1.

Features of HAV infection for six patients^a

Parameter	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6
Age (yr)/sex	34/M	47/M	25/M	34/M	28/M	15/F
Date of symptom onset (day/mo/yr)	10/11/2002	7/4/2003	20/4/2003	4/5/2003	3/8/2003	28/9/2003
Place of contamination	Paris	Paris	Paris	Paris	Cape Verde	Morocco
Risk factor	MSM HIV	MSM HIV	MSM HIV	Unknown	International travel	International travel
Date of serum sampling (day/mo/yr)	14/11/2002	15/4/2003	22/4/2003	8/5/2003	7/8/2003	8/10/2003
Date of saliva sampling (day/mo/yr)	21/11/2002	17/4/2003	25/4/2003	9/5/2003	8/5/2003	8/10/2003
ALT (IU/ml)	632	238	2,800	6,150	3,600	4,000
Serum VP1/2A RNA	+	+	+	+	+	+
Serum RNA quantification	4.9 × 106	7.3 × 103	2.3 × 107	3.6 × 105	2.2 × 104	4.1 × 104
Saliva VP1/2A RNA	+	−	+	+	+	+
Saliva RNA quantification	9.3 × 102	/	1.9 × 104	3.5 × 103	<6.0 × 102	1.1 × 103
Copies in serum/copies in saliva (log units)	2.25	/	1.72	1.29	>1.6	1.52
HAV genotype	IA	IA	IA	IA	IB	IA

^aM, male; F, female; ALT, alanine aminotransferase level; MSM, men having sex with men; +, presence; −, absence; /, not performed.